Eyenovia Inc Stock Price, News & Analysis

Eyenovia, Inc. (NASDAQ: EYEN) announced plans to release its second quarter financial results for 2022 on August 10, after market close. The results will be followed by a conference call at 4:30 PM ET, where management will discuss financial and operational performance. Participants can join via phone or through a live webcast available on the company's investor relations page. The event will be archived on Eyenovia's website for one year, allowing investors to access the information at their convenience.

Eyenovia, Inc. has appointed Michael Rowe as its new CEO, effective August 1, 2022. Rowe, previously the Chief Operating Officer, brings extensive experience in the ophthalmic industry, having been instrumental in the company’s operations and product development. The transition follows Dr. Sean Ianchulev's move to Chairman. Eyenovia expects significant developments, including the potential approval of MydCombi and the progress of strategic partnerships with Bausch+Lomb and Arctic Vision. Rowe’s leadership is anticipated to enhance company momentum towards commercial-stage operations.

Eyenovia announced the operational launch of its new manufacturing facility in Redwood City, CA, enhancing internal capabilities for Optejet manufacturing, including drug loading and packaging. This facility aims to complement existing contract manufacturing partnerships. Additionally, Bren Kern has been appointed as Senior Vice President of Manufacturing and Operations, expected to strengthen the team's efforts in product commercialization. The company reaffirmed timelines for the VISION-2 Phase 3 trial of MicroLine, anticipating topline data in Q3 2022, with significant market interest in their technology.

Eyenovia, Inc. (Nasdaq: EYEN) has announced the appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as independent members of its Board of Directors, expanding the board from six to eight members. Dr. Strahlman brings extensive experience from roles at Becton, Dickinson and Company and GlaxoSmithKline, while Dr. Palanki has significant expertise in commercial strategy in biopharmaceuticals. The CEO expressed confidence that their expertise will enhance the company's leadership as it approaches crucial clinical and regulatory milestones.

Eyenovia (NASDAQ: EYEN) announced that Arctic Vision has enrolled its first patient in a Phase 3 clinical trial for ARVN003 (MicroLine), a pharmacologic treatment for presbyopia, marking a significant milestone in China. This trial is notable as it's the first of its kind in the country, validated by the exclusive licensing agreement between Eyenovia and Arctic Vision signed in August 2020. The partnership also includes Eyenovia's candidates, MicroPine for pediatric myopia and MydCombi for pharmacologic mydriasis, further targeting unmet medical needs in the region.

Eyenovia, Inc. (NASDAQ: EYEN) will host its Annual Meeting of Stockholders virtually on June 16, 2022, at 10:00 am EDT. Stockholders registered by April 18, 2022, can vote via an online portal until June 15, 2022. It is essential for stockholders to register by 9:45 am EDT on the meeting day. The meeting aims to engage stockholders and encourage them to submit their proxies in advance. Eyenovia focuses on microdose array print (MAP™) therapeutics for various ophthalmic conditions, including presbyopia and myopia progression.

Eyenovia, Inc. (NASDAQ: EYEN) announced its Annual Meeting of Stockholders will be held virtually on June 16, 2022, at 10:00 AM EDT. Stockholders of record as of April 18, 2022, can vote in advance of the meeting. An online portal is available for viewing proxy materials and voting. Registration for the meeting must be completed by 9:45 AM EDT on the day of the meeting. The company focuses on developing microdose array print (MAP™) therapeutics aimed at treating eye conditions such as mydriasis and presbyopia.

Eyenovia, Inc. (NASDAQ: EYEN) announced a leadership transition as CEO Dr. Sean Ianchulev will step down and become non-executive Chairman of the Board. Ianchulev, a co-founder, will retain a consulting role to support ongoing clinical trials. The company is searching for a new CEO to lead it towards commercial growth, especially with upcoming milestones like the Mydcombi NDA re-filing and Phase III studies for its Microline presbyopia program. This transition marks a significant step for Eyenovia as it prepares for the next stage in its development.

Eyenovia, Inc. (NASDAQ: EYEN) reported its Q1 2022 financial results, ending with approximately $34.6 million in cash and cash equivalents. The company is on track for the NDA resubmission of Mydcombi in Q3 2022 and expects topline data from the VISION-2 Phase 3 study for MicroLine by mid-year. The net loss for the quarter was approximately $(7.3) million or $(0.24 per share, a deterioration from a $(5.4) million net loss in Q1 2021. The company has made progress on FDA device validation testing and has launched presbyopia studies demonstrating the efficacy of its Optejet technology.